Why Eli Lilly Stock Climbed Today

Axe Cap view

Eli Lilly’s Surge: Lessons for South African Investors

Eli Lilly’s strong quarterly results highlight the power of innovative healthcare bets—something JSE investors can learn from amid local healthcare challenges.

Eli Lilly’s recent 4.86% jump after beating earnings expectations underscores how innovation in healthcare drives value. Their obesity drugs, Mounjaro and Zepbound, growing over 40% and 90% respectively, aren’t just hitting sales targets—they’re reshaping market demand. For South Africans, the lesson is clear: healthcare innovation can offer durable growth even when economic headwinds persist. While JSE counters like Aspen or Adcock Ingram don’t mimic Lilly’s scale or pipeline, the big banks—Standard Bank and FirstRand—are increasingly exposed to the health sector's financing. Watch these connections closely, as strong global healthcare trends can indirectly boost local financials through improved loan growth and risk profiles. On currencies, a stronger USD often tightens capital flows to emerging markets like SA, pressuring the rand (USD/ZAR). That makes overlooking the currency’s impact on multisector portfolios a mistake. Our view: stay selective—consider FirstRand for exposure, but avoid rushing into local pharma names without clear catalyst. A sudden US regulatory change or a shift in currency dynamics could derail this narrative. this is just our opinion and not financial advice